tocilizumab - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.04 [0.77, 1.41]< 18%5 studies (5/-)40.5 %some concernnot evaluable moderatecrucial-
deaths 0.94 [0.72, 1.23]< 129%7 studies (7/-)67.7 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.04 [0.78, 1.38]< 10%3 studies (3/-)39.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.56 [0.26, 1.20]< 10%1 study (1/-)93.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.44 [1.06, 1.96]> 144%2 studies (2/-)99.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.96 [0.65, 1.43]< 126%3 studies (3/-)57.8 %some concernnot evaluable moderateimportant-
hospital discharge 0.97 [0.79, 1.20]> 10%1 study (1/-)38.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.67 [0.39, 1.14]< 10%1 study (1/-)93.0 %some concernnot evaluable moderateimportant-
ICU admission 0.48 [0.25, 0.94]< 10%1 study (1/-)98.4 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.90 [0.65, 1.23]< 119%4 studies (4/-)74.6 %some concernnot evaluable moderateimportant-
adverse events 1.21 [0.87, 1.67]< 121%3 studies (3/-)12.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.